AI-Driven Model Validated to Predict Risk of CKD Progression
Boehringer Ingelheim and Carelon Research conducted the first large-scale U.S. validation of a new AI-driven tool to predict the risk of CKD progression.
BI & Gubra Join Forces to Identify Peptides | Boehringer Ingelheim US
BI & Gubra announce research & licensing agreement focused on the identification & validation of targets & peptide compounds for the treatment of obesity.
Boehringer Ingelheim Statement on ATS/ERS/JRS/ALAT Guidelines for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
Boehringer Ingelheim welcomes the new guidance issued by American Thoracic Society, European Respiratory Society, Japanese Respiratory Society and Asociación Latinoamericana de Tórax for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis • K
Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim collaborate on first study to evaluate nintedanib in patients with fibrosing ILD following COVID-19 infection
Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim collaborate on first study to evaluate nintedanib in patients with fibrosing ILD following COVID-19 infection
Manami Tsutsumi, Senior Associate Director in Research & Development describes what it is like working on the cutting edge of pharmaceutical development.
Our innovation strategy focuses on developing a deep understanding of disease, identifying relevant disease mechanisms and using adequate therapeutic modalities to address them
Boehringer Ingelheim today announced that the first patient was enrolled in the SENSCIS™ (Safety and Efficacy of Nintedanib in SystemicSClerosIS) study.